Carrieri P B, Orefice G, Sorge F
Department of Neurology, 2nd Medical School, University of Naples, Italy.
Acta Neurol Scand. 1988 Jun;77(6):433-6. doi: 10.1111/j.1600-0404.1988.tb05935.x.
In a double-blind randomized trial of 42 patients with classic or common migraine, indobufen, an antiplatelet drug that inhibits platelet cyclo-oxygenase, was compared with placebo in the prevention of migraine. The duration of treatment was 3 months, and the efficacy was assessed on the basis of the following variables: frequency and duration of attacks, headache index (intensity x frequency); 35 completed the investigation. Indobufen at an oral dose of 200 mg b.i.d. reduced all the variables considered, where placebo did not. The drug was generally well tolerated. The findings of the preliminary trial suggest that indobufen might be an useful alternative in the prophylaxis of migraine.
在一项针对42例典型或普通偏头痛患者的双盲随机试验中，将抑制血小板环氧化酶的抗血小板药物吲哚布芬与安慰剂进行比较，以预防偏头痛。治疗持续时间为3个月，并根据以下变量评估疗效：发作频率和持续时间、头痛指数（强度×频率）；35例完成了研究。口服剂量为200mg，每日两次的吲哚布芬降低了所有所考虑的变量，而安慰剂则没有。该药物总体耐受性良好。初步试验结果表明，吲哚布芬可能是预防偏头痛的一种有用的替代药物。
